Opfolda
Payments companies reported to CMS as associated with Opfolda. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.
By year
Payments reported as associated with Opfolda, per program year, as reported to CMS.
Who makes it
Specialties most often involved
Where the associated payments went, by the receiving clinician's specialty.
Clinicians most associated with Opfolda
These are the largest totals companies reported as associated with Opfolda. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.
| Clinician | Location | Specialty | Associated payments (2023-2025) |
|---|---|---|---|
| Martin Bedigian | Livingston, NJ | Internal Medicine | $59,400.00 |
| Tahseen Mozaffar | Orange, CA | Neuromuscular Medicine (Psychiatry & Neurology) | $55,438.35 |
| Priya Kishnani | Durham, NC | Pediatrics | $44,516.21 |
| Carlos Prada | Chicago, IL | Clinical Genetics (M.D.) | $19,720.31 |
| Ermal Aliu | Hershey, PA | Pediatrics | $15,454.90 |
| Staci Kallish | Philadelphia, PA | Clinical Genetics (M.D.) | $14,678.64 |
| Mazen Dimachkie | Houston, TX | Neurology (Psychiatry & Neurology) | $11,353.48 |
| Nizar Chahin | Portland, OR | Neurology (Psychiatry & Neurology) | $11,289.17 |
| Barry Byrne | Gainesville, FL | Pediatric Cardiology | $9,354.90 |
| Paul Mcintosh | Philadelphia, PA | Neuromuscular Medicine (Psychiatry & Neurology) | $9,246.26 |
Prescribed Opfolda?
See what its makers reported for your doctor. Two steps, private, no account.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.